PBRM1 and renal cell adenocarcinoma: Many studies have demonstrated that the differentiation of macrophages and ratio of M1/M2 macrophages are related to tumor therapy, in which the M1 macrophage phenotype is classified to have an anti‐tumor effect and M2 has the opposite effect.[36, 37, 38] We previously showed that the status of PBRM1 may be related to RCC immunotherapy.[33] Our data demonstrate that alterations in PBRM1 particularly promote polarization of M1 macrophages, thereby inducing remodeling of the immune microenvironment and augmenting immunotherapeutic effects.